These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 15749678

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
    Hillmen P.
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treatment of fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ.
    Cancer; 2009 Jul 01; 115(13):2824-36. PubMed ID: 19402170
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [Abstract] [Full Text] [Related]

  • 31. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S.
    Clin Adv Hematol Oncol; 2008 Jan 01; 6(1):23-4. PubMed ID: 18322437
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Alemtuzumab: what is the secret to safe therapy?
    Elter T, Hallek M, Montillo M.
    Clin Adv Hematol Oncol; 2011 May 01; 9(5):364-73. PubMed ID: 21685865
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
    Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M, German CLL Study Group (GCLLSG).
    Leukemia; 2004 Jun 01; 18(6):1093-101. PubMed ID: 15071604
    [Abstract] [Full Text] [Related]

  • 38. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J.
    J Clin Oncol; 2007 Dec 10; 25(35):5616-23. PubMed ID: 17984186
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M, Schinkoethe T, Elter T.
    Cancer Invest; 2005 Dec 10; 23(6):488-96. PubMed ID: 16203656
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.